FDA approves Icotrokinra (ICOTYDE) as an oral peptide

United States: On March 18, 2026, the U.S. Food and Drug Administration (FDA) approved Icotrokinra (brand name ICOTYDE) from Johnson & Johnson as the first targeted oral peptide to inhibit the interleukin-23 receptor (IL-23R). The approval covers adults and adolescents aged 12 and older weighing at least 40 kg who have moderate to severe plaque psoriasis and are candidates for systemic therapy or phototherapy. This is the first time an orally administered peptide medication in tablet form has shown effective treatment of a chronic inflammatory disease without injections.

Key facts about the FDA approval of Icotrokinra

• Icotrokinra is the first approved oral peptide that specifically blocks the IL-23 receptor, thereby interrupting the inflammatory processes in plaque psoriasis.
• In the phase 3 studies ICONIC-ADVANCE 1 and 2, Icotrokinra achieved higher response rates than placebo and the oral comparator drug Deucravacitinib by week 24 and in the further course.
• The approval program includes four phase 3 studies with 2,500 patients, in which around 70% of those treated achieved clear or almost clear skin (IGA 0/1) at week 16.
• As a tablet for oral administration, Icotrokinra prevents local injection site reactions and facilitates treatment adherence for patients with a fear of needles.
• For peptide research, the approval sets a pioneering precedent for bioavailable oral peptide therapies beyond injectable biologics.

What is Icotrokinra and how does the oral peptide work?

Icotrokinra is an orally bioavailable macrocyclic peptide that binds selectively and with high affinity to the interleukin-23 receptor (IL-23R) to specifically block pro-inflammatory signals in plaque psoriasis. Its ring-shaped molecular structure protects the active substance from rapid enzymatic degradation in the digestive tract. By specifically switching off the receptor, the inflammatory cascade is halted directly in the skin tissue. A review on PubMed (2026)^[1] summarizes the clinical phase 2 and phase 3 studies in moderate to severe plaque psoriasis.

The crucial difference from established peptide active substances such as the GLP-1 receptor agonists Semaglutide and Tirzepatide lies in its administration as a tablet. Oral peptides require high molecular stability to survive the gastrointestinal passage unharmed and reach the bloodstream intact. This progress shows that targeted oral dosage forms are practical in peptide therapy.

What do the clinical studies show regarding efficacy and response rates?

The data from four phase 3 studies with 2,500 patients confirm the superior efficacy of Icotrokinra in direct comparison with placebo and Deucravacitinib, as outlined in the report on drugslib.com (2026)^[6]. In the pivotal main studies ICONIC-ADVANCE 1 and 2, once-daily administration led to significantly better skin outcomes by week 24, according to the publication (2025)^[5]. As early as week 16, around 70% of participants achieved complete or almost complete skin clearance (IGA 0/1), and 55% achieved a 90% improvement in skin condition (PASI-90)^[6].

These therapeutic response rates remained stable in the ICONIC-ADVANCE long-term analyses (2026)^[7] up to week 52, without any new safety signals. Patients who initially received placebo or Deucravacitinib and later switched to Icotrokinra achieved similarly high success rates. A systematic meta-analysis (2026)^[8] underscores the efficacy and the favorable benefit-risk profile of the substance.

How safe is Icotrokinra compared to injections?

The safety profile of Icotrokinra proved favorable in the clinical studies, with mainly mild side effects such as gastrointestinal complaints being documented. A specialist article on PMC (2025)^[2] reports the absence of serious substance-related adverse events, and the 52-week results of the ICONIC-ADVANCE studies also showed no unexpected risks^[7]. Since these findings come from standardized study populations, any medical treatment requires individual medical supervision.

Compared to injectable biologics, the oral form offers the advantage that pain and reactions at the injection site are completely eliminated. Local tissue reactions are typical side effects of injectable IL-23 inhibitors such as Guselkumab and Risankizumab, as well as IL-17 inhibitors such as Ixekizumab and Secukinumab^[8]. According to the PMC analysis^[2], needle-free administration can noticeably improve treatment adherence in everyday practice.

What does Icotrokinra mean for the future of peptide therapy?

The regulatory approval of Icotrokinra establishes orally bioavailable peptide active substances as a fully-fledged therapeutic option alongside classic injections. While injectable preparations for metabolic indications have so far dominated the peptide market, Icotrokinra, as a prescription medicine, opens up new avenues for peptide chemistry in autoimmune diseases. The product is subject to strict pharmaceutical regulations and does not belong in unregulated supply channels.

You can find detailed information on mechanisms of action, research findings, and regulatory requirements for peptide substances in the Peptide Library. For the proper handling and dosage calculation of injectable forms, the Injection Calculator is available to you.

Icotrokinra is a prescription-only finished medicinal product and not an over-the-counter research product for purchase through unregulated gray markets. If you want to learn about quality standards, purity risks, and counterfeiting dangers associated with peptide preparations, the Protection Area offers you reliable guidance. This text serves exclusively for informational purposes and in no way replaces professional medical diagnosis or advice.